GlassScriptPhysician profile
Zainab Obaidi
NPI 1891102505
$39,023.38
in general payments reported to CMS, 2019-2025
12 companies · $23K in 2025
The $23K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $2,345 · 2024: $13K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Consulting Fee: $10K · Travel and Lodging: $5,958 · Food and Beverage: $4,466 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,836 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $300 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $14,012.50 |
| Consulting Fee | $10,200.47 |
| Travel and Lodging | $5,958.49 |
| Food and Beverage | $4,465.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,835.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $300.00 |
| Education | $132.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $20,842.97 | 2024-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $12,064.84 | 2023-2025 | |
| Amgen INC. | $4,745.97 | 2023-2025 | Tavneos, Uplizna |
| Alexion Pharmaceuticals, INC. | $297.33 | 2022-2024 | Soliris |
| Aurinia Pharma U.S., INC. | $246.45 | 2023-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $231.54 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.94 | 2023 | |
| Apellis Pharmaceuticals, INC. | $153.65 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $120.57 | 2025 | |
| Glaxosmithkline, LLC. | $116.18 | 2023 | Benlysta |
| Novo Nordisk INC | $32.27 | 2025 | Ozempic |
| Genentech, INC. | $13.67 | 2025 | Gazyva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zainab Obaidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.